Paper Details

  1. Home
  2. Paper Details

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.

Author: AerssensAnnelies, AmanullahArshad, DrameMamadou, InnisBruce L, JainVarsha K, Leroux-RoelsGeert, LiPing, MaesCathy, Ofori-AnyinamOpokua, SchuindAnne

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Equivalence TrialA clinical trial designed to show that a new treatment is equivalent in efficacy/safety to an existing treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This phase 3, placebo-controlled, observer-blind trial compared co-administration versus separate administration of an inactivated quadrivalent influenza vaccine (IIV4) with a 23-valent pneumococcal polysaccharide vaccine (PPV23) in adults at high risk of complications from influenza and pneumococcal infection. The study found that co-administration did not reduce antibody responses to either vaccine and may improve vaccine uptake.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: We compared co-administration versus separate administration of an inactivated quadrivalent influenza vaccine (IIV4) with a 23-valent pneumococcal polysaccharide vaccine (PPV23) in adults at high risk of complications of influenza and pneumococcal infection. METHODS: This phase III, p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.vaccine.2017.09.012

データ提供：米国国立医学図書館（NLM）

Influenza and Pneumococcal Vaccines: A Two-Pronged Approach to Desert Immunity

Protecting ourselves from infectious diseases is like building a fortress against the elements of the desert. This study focused on the effectiveness and safety of co-administering two vaccines: an inactivated quadrivalent influenza vaccine (IIV4) and a 23-valent pneumococcal polysaccharide vaccine (PPV23). The researchers conducted a clinical trial to compare the effectiveness of co-administration versus separate administration of the two vaccines. They found that co-administering the two vaccines was safe and did not reduce the effectiveness of either vaccine. This is a significant finding, suggesting that it's possible to strengthen our defenses against both influenza and pneumococcal infections simultaneously. This study provides a practical solution for those navigating the desert of disease, allowing us to build a more robust immune system.

Co-Administration: Strengthening Our Immune Fortress

The study suggests that co-administering influenza and pneumococcal vaccines is a safe and effective strategy for building a stronger immune system, creating a more robust fortress against the elements of the desert.

Protecting Ourselves in the Desert of Disease

Vaccinations play a crucial role in protecting ourselves from infectious diseases, helping us navigate the desert of disease with greater resilience. It's important to stay informed about vaccine recommendations and talk to your doctor about the best vaccination strategy for you.

Dr.Camel's Conclusion

This study presents a promising strategy for strengthening our defenses against infectious diseases, offering a two-pronged approach to building a more robust immune system. By effectively combining vaccinations, we can enhance our resilience in the desert of disease, allowing us to navigate its challenges with greater confidence. This research highlights the power of collaboration in healthcare, emphasizing the importance of working together to build a stronger and healthier future. Just like a group of camels working together to cross a vast desert, we can achieve greater outcomes when we collaborate and share knowledge.

Date :
  1. Date Completed 2018-05-29
  2. Date Revised 2018-05-29
Further Info :

Pubmed ID

28987445

DOI: Digital Object Identifier

10.1016/j.vaccine.2017.09.012

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.